Ali McBride speaks about three new target therapies that have recently come to market.
This year, really even this month, we can say the month of multiple myeloma. We have seen three new target therapies come out. We had seen Elotuzumab, Ixazomib, and also saw Daratumumab coming to market.
We actually have three different cadres for actual treatments, and in the relapsed refractory setting. That really has changed the current marketplace, and also evaluation of those patients, in the relapsed refractory setting.
Now we're going to see the idea, the content for who gets what treatment. The question comes about is what will be the sequence of therapy? We have seen many times, and times again when new therapies come out.
We're still evaluating those therapies where there's monotherapy in combination, and also in multiple combination regimens, they all need to be followed on.
At this point, when the start of new drug therapies, some very good prolonged PFS response rates, and that provides these new options for treatment which weren't there just several years ago. It's a great time right now in terms there's new therapies coming on.
We have a lot of work to do in terms of understanding sequencing, and that will actually be the most critical question when we're looking at patients who have multiple myeloma, and also what treatment regimen they get as well as if those patients can be transplant eligible or transplant ineligible down the line as well for the initial diagnosis.